Literature DB >> 27320213

Optimizing sequence coverage for a moderate mass protein in nano-electrospray ionization quadrupole time-of-flight mass spectrometry.

Ryan Matsuda1, Venkata Kolli1, Megan Woods1, Eric D Dodds1, David S Hage2.   

Abstract

Sample pretreatment was optimized to obtain high sequence coverage for human serum albumin (HSA, 66.5 kDa) when using nano-electrospray ionization quadrupole time-of-flight mass spectrometry (nESI-Q-TOF-MS). Use of the final method with trypsin, Lys-C, and Glu-C digests gave a combined coverage of 98.8%. The addition of peptide fractionation resulted in 99.7% coverage. These results were comparable to those obtained previously with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The sample pretreatment/nESI-Q-TOF-MS method was also used with collision-induced dissociation to analyze HSA digests and to identify peptides that could be employed as internal mass calibrants in future studies of modifications to HSA.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Collision-induced dissociation; Human serum albumin; Internal calibration; Nano-electrospray ionization quadrupole time-of-flight mass spectrometry; Sample pretreatment; Sequence coverage

Mesh:

Substances:

Year:  2016        PMID: 27320213      PMCID: PMC4965299          DOI: 10.1016/j.ab.2016.06.014

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  11 in total

Review 1.  Mass spectrometry-based proteomics.

Authors:  Ruedi Aebersold; Matthias Mann
Journal:  Nature       Date:  2003-03-13       Impact factor: 49.962

2.  An accurate and clean calibration method for MALDI-MS.

Authors:  Bosong Xiang; Mindy Prado
Journal:  J Biomol Tech       Date:  2010-09

3.  Comparison of modification sites formed on human serum albumin at various stages of glycation.

Authors:  Omar S Barnaby; Ronald L Cerny; William Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2010-10-27       Impact factor: 3.786

Review 4.  The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update.

Authors:  Annunziata Lapolla; Domenico Fedele; Roberta Seraglia; Pietro Traldi
Journal:  Mass Spectrom Rev       Date:  2006 Sep-Oct       Impact factor: 10.946

5.  Quantitative analysis of glycation sites on human serum albumin using (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Omar S Barnaby; Chunling Wa; Ronald L Cerny; William Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2010-04-13       Impact factor: 3.786

6.  Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-labeling and MALDI-TOF MS.

Authors:  Omar S Barnaby; Ronald L Cerny; William Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2011-05-13       Impact factor: 3.786

7.  Obtaining high sequence coverage in matrix-assisted laser desorption time-of-flight mass spectrometry for studies of protein modification: analysis of human serum albumin as a model.

Authors:  Chunling Wa; Ron Cerny; David S Hage
Journal:  Anal Biochem       Date:  2005-11-28       Impact factor: 3.365

Review 8.  A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease.

Authors:  Qibin Zhang; Jennifer M Ames; Richard D Smith; John W Baynes; Thomas O Metz
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

Review 9.  Review: Glycation of human serum albumin.

Authors:  Jeanethe Anguizola; Ryan Matsuda; Omar S Barnaby; K S Hoy; Chunling Wa; Erin DeBolt; Michelle Koke; David S Hage
Journal:  Clin Chim Acta       Date:  2013-07-24       Impact factor: 3.786

10.  Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Chunling Wa; Ronald L Cerny; William A Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2007-06-23       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.